LRRK2 and Parkinson disease: They demonstrated that simBOs derived from a PD patient with LRRK2-G2019S exhibited increased LRRK2 activity and a reduced DA neuronal number that can be mitigated by the treatment of these mutant organoids with the LRRK2 inhibitor PFE-360 [196].